Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

50.41 -0.74 (-1.45%)

Official Closing Price Updated: 4:10 PM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

46 47 Next >

Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗

April 24, 2023

Via Benzinga

United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗

April 21, 2023

The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.

Via Benzinga

Why Shares of Bellus Health Skyrocketed This Week ↗

April 20, 2023

The company has received a buyout offer from GSK.

Via The Motley Fool

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

April 18, 2023

From BELLUS Health Inc.

Via Business Wire

This Favorable Sign Appears On GSK's Chart ↗

April 14, 2023

Via Benzinga

This House of Representative Just Sold Up To $100K In GSK Stock ↗

April 05, 2023

Via Benzinga

GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks ↗

March 30, 2023

Via Benzinga

Why BELLUS Health Stock Is Rocketing Higher Today ↗

April 18, 2023

A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

April 18, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal ↗

April 18, 2023

Shares of its takeover candidate nearly doubled on the news.

Via Investor's Business Daily

Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories ↗

April 18, 2023

Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs

Via Benzinga

Why Is Bellus Health (BLU) Stock Up 98% Today? ↗

April 18, 2023

Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK).

Via InvestorPlace

GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition ↗

April 18, 2023

Via Benzinga

Can Pfizer Beat GSK and Moderna in This $10 Billion Market? ↗

April 13, 2023

There's such a big need in preventing RSV that multiple companies should be big winners.

Via The Motley Fool

Why Shares of Adaptimmune Therapeutics Jumped Tuesday ↗

April 11, 2023

The company bulks up its pipeline by regaining the rights to two of its clinical programs.

Via The Motley Fool

Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments ↗

April 11, 2023

The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...

Via Benzinga

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

April 11, 2023

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...

Via Newsfile

Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging

April 10, 2023

While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat

Via MarketBeat

Topics Artificial Intelligence

2 Top Biotech Stocks to Buy in April ↗

April 04, 2023

Right now you can pick up these stocks on the dip.

Via The Motley Fool

Could This Move by Johnson & Johnson Equal Billions for Moderna? ↗

April 02, 2023

An RSV vaccine could be a driver of blockbuster revenue.

Via The Motley Fool

Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis ↗

March 31, 2023

A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),...

Via Benzinga

Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva ↗

March 31, 2023

Via Benzinga

SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

March 30, 2023

SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions

Via Spotlight Growth

Why Is Scynexis (SCYX) Stock Up 69% Today? ↗

March 30, 2023

Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme.

Via InvestorPlace

Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug ↗

March 30, 2023

Via Benzinga

Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review ↗

March 29, 2023

Via Benzinga

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out ↗

March 29, 2023

The company says it's refocusing its portfolio to focus on transformational medicines.

Via Investor's Business Daily

GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients ↗

March 28, 2023

Via Benzinga

Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

March 27, 2023

Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.

Via MarketBeat

Recent Stock Purchases For March 2023 ↗

March 25, 2023

As readers may know by now, I make stock purchases every single month, no matter what is going on in the world. This month, I went heavier than I normally do, deploying over $3,000. Let's take a look.

Via Talk Markets

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

46 47 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.